NCT02409472View on ClinicalTrials.gov

Intensive Versus Minimal Surveillance of Patients With Resected Dukes B2-C Colorectal Carcinoma

NACompletedINTERVENTIONAL
Enrollment

1,242

Participants

Timeline

Start Date

April 30, 1998

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Colorectal CancerSurveillance
Interventions
OTHER

surveillance program after completion of primary treatment

These are two different surveillance programs for Dukes B2-C colorectal cancer patients who have no evidence of disease at the end of their front line treatment (surgery and adjuvant radio-chemotherapy, if indicated). These programs differ greatly in the frequency of diagnostic imaging. They had similar schedules of physical examinations and carcinoembryonic antigen (CEA) assessments.

All Listed Sponsors
lead

Mario Negri Institute for Pharmacological Research

OTHER

NCT02409472 - Intensive Versus Minimal Surveillance of Patients With Resected Dukes B2-C Colorectal Carcinoma | Biotech Hunter | Biotech Hunter